Orthner C L
J Lab Clin Med. 1984 Nov;104(5):816-28.
Antihemophilic factor concentrates were surveyed for amidolytic activity on the chromogenic substrates S2238, S2302, S2222, and S2251, which are sensitive to thrombin, kallikrein, factor Xa, and plasmin, respectively. For antihemophilic factor concentrates from two manufacturers, the rates of amidolysis of S2238 and S2302 were approximately an order of magnitude greater than the rates of amidolysis of S2222 and S2251. The S2238 and S2302 activities were characterized by quantitating their interactions with specific substrates or inhibitors. The Km for amidolysis of S2238 was 558 mumol/L, which is 80 times higher than for thrombin but in close agreement to the reported value for activated protein C. The S2238 activity was not inhibited by the thrombin-specific inhibitor dansylarginine N-(3-ethyl-1,5-pentanediyl)amide, nor by soybean trypsin inhibitor or micromolar concentrations of antithrombin III in the presence of heparin. The S2238 activity was inhibited by D-Phe-Pro-Arg-CH2Cl, but with an estimated second-order rate constant of 3 X 10(5) mol/L-1 minute-1, approximately 1000 times less than for thrombin. These data are consistent with the identity of the S2238 activity as activated protein C. On the other hand, the S2302 activity in antihemophilic factor concentrates was most likely attributable to kallikrein. This was based on the agreement with authentic kallikrein of the Km for S2302 of 154 mumol/L as well as by the rapid inactivation by nanomolar concentrations of the kallikrein-specific inhibitor D-Phe-Phe-Arg-CH2Cl. However, the relative resistance of the S2302 activity to inhibition by soybean trypsin inhibitor or antithrombin III and the partial inhibition by aprotinin suggested that a large proportion of the kallikrein was bound to alpha 2-macroglobulin. This was confirmed by immunoprecipitation using specific anti alpha 2-macroglobulin IgG. The potential for proteolysis of factor VIII:von Willebrand protein during its purification from antihemophilic factor concentrates was demonstrated, and the proteolyzed factor VIII coagulant species was characterized. High-pressure gel permeation chromatography of purified factor VIII:von Willebrand protein at high ionic strength resulted in two sharp peaks of factor VIII procoagulant activity. The earlier eluting peak corresponded with the void volume, and the later peak eluted with an apparent molecular weight of 53,000 daltons. Immediately after separation, the 53,000-dalton factor VIII coagulant had at least a 100-fold higher specific activity than the factor VIII coagulant present in the void volume. However, the 53,000-dalton factor VIII coagulant was labile, with a half-life of 80 minutes.(ABSTRACT TRUNCATED AT 400 WORDS)
检测了抗血友病因子浓缩物对生色底物S2238、S2302、S2222和S2251的酰胺水解活性,这些底物分别对凝血酶、激肽释放酶、Xa因子和纤溶酶敏感。对于来自两家制造商的抗血友病因子浓缩物,S2238和S2302的酰胺水解速率比S2222和S2251的酰胺水解速率大约高一个数量级。通过定量S2238和S2302与特定底物或抑制剂的相互作用来表征其活性。S2238酰胺水解的Km为558μmol/L,比凝血酶高80倍,但与活化蛋白C的报道值相近。S2238活性不受凝血酶特异性抑制剂丹磺酰精氨酸N-(3-乙基-1,5-戊二醇)酰胺抑制,也不受大豆胰蛋白酶抑制剂或肝素存在下微摩尔浓度的抗凝血酶III抑制。D-Phe-Pro-Arg-CH2Cl可抑制S2238活性,但其估计的二级速率常数为3×10⁵mol/L⁻¹分钟⁻¹,约为凝血酶的1000倍。这些数据与S2238活性为活化蛋白C一致。另一方面,抗血友病因子浓缩物中的S2302活性很可能归因于激肽释放酶。这是基于其S2302的Km为l54μmol/L与 authentic激肽释放酶一致,以及纳摩尔浓度的激肽释放酶特异性抑制剂D-Phe-Phe-Arg-CH2Cl可使其快速失活。然而,S2302活性对大豆胰蛋白酶抑制剂或抗凝血酶III抑制的相对抗性以及抑肽酶的部分抑制表明,大部分激肽释放酶与α2-巨球蛋白结合。使用特异性抗α2-巨球蛋白IgG进行免疫沉淀证实了这一点。证明了从抗血友病因子浓缩物中纯化因子VIII:血管性血友病因子期间其被蛋白水解的可能性,并对蛋白水解的因子VIII凝血成分进行了表征。在高离子强度下对纯化的因子VIII:血管性血友病因子进行高压凝胶渗透色谱分析,产生了两个尖锐的因子VIII促凝活性峰。较早洗脱的峰对应于空体积,较晚的峰以表观分子量53,000道尔顿洗脱。分离后立即,53,000道尔顿的因子VIII凝血剂的比活性至少比存在于空体积中的因子VIII凝血剂高100倍。然而,53,000道尔顿的因子VIII凝血剂不稳定,半衰期为80分钟。(摘要截短为400字)